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Abstract 
BACKGROUND: Asthma is a common chronic inflammatory respiratory disease more common in children. Microbial 
agents such as viruses are a common trigger of asthma. Coronavirus disease 2019 (COVID-19) is a pandemic 
disease that could lead to the exacerbation of allergic disorders such as asthma. The aim of this study is to write a 
narrative review of COVID-19 and asthma condition. 
METHODS: We searched in Google scholar, PubMed, and Scopus databases with keywords COVID-19, asthma, 
corticosteroid, and inhaled steroids. 
RESULTS: We found a few original articles on the combined subject of asthma and COVID-19. More than 50% of 
our data is expert comments at valid websites such as https://www.AAAAI.org or https://ginasthma.org. The typical 
treatment recommended in the exacerbation of asthma or chronic obstructive pulmonary disease (COPD) included 
the use of corticosteroids. The routine use of corticosteroids in patients with COVID-19 without obstructive lung 
disease is not advised, as it may prolong viral replication. 
CONCLUSION: Patients with asthma need to continue on their preventive asthma medication, such as inhaled 
corticosteroids (ICS) in pandemic COVID-19. 
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Introduction1 
Betacoronavirus named 2019 novel coronavirus 
(2019-nCoV) or severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) causing 
coronavirus disease 2019 (COVID-19) is a 
pandemic that can involve all people. 
Generally, clinical manifestations of COVID-19 
are fever, cough, nausea, vomiting, diarrhea, 
myalgia, and fatigue. Laboratory abnormalities 
are leukopenia, thrombocytopenia, increased 
aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT) levels, creatine kinase 
or lactate dehydrogenase enzymes, C-reactive 
protein (CRP), and erythrocyte sedimentation 
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rate (ESR).1 Patients with asthma have a great 
fear of the worse consequences. Asthma is a 
common disease in the world involving more 
than 300 million people wordlwide.2-4 Although 
asthma does not affect intelligence quotient 
(IQ), it has some degree of morbidity, 
mortality, and a high burden on the family and 
country.5,6 Etiology of asthma is not exactly 
clear, however the genetic and environmental 
factors are involved in this complication.7-9 
Viral infections include respiratory syncytial 
virus (RSV), influenza, parainfluenza, 
adenovirus, coronavirus, and enterovirus, 
which are common triggers of asthma 
exacerbation.10 Currently, based on the 
evidence, there is not increased infection rates 
of COVID-19 in those with asthma. The 
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(CDC), United States statements revealed that 
there is a higher risk of severe diseases in 
moderate to severe asthma.11 Asthma 
management includes allergen avoidance, 
short-acting beta2 adrenergic agents, long-
acting beta2 agonist agents, inhaled 
corticosteroids (ICS), systemic steroids, specific 
immunotherapy, etc.12-14 At present, there is a 
lack of data on the use of steroids in treating 
asthma.15 ICS might be increasing the risks of 
respiratory infections in patients with asthma. 
Higher doses of ICS induces more risk of 
respiratory infections. In contrast, there is 
some evidence that ICS may also reduce  
some respiratory infections. For example, 
formoterol and budesonide may inhibit 
rhinovirus infection.11 
Materials and Methods 
We searched in Google scholar, PubMed, and 
Scopus databases with keywords COVID-19, 
asthma, corticosteroid, and inhaled steroids. 
We found a few articles and wrote a narrative 
review article. Some of them were full-text 
articles and others were expert comments. We 
did not have a limitation on time. Each of the 
articles contained English abstract and  
full-text, and expert comments were included 
in this review.  
Results 
We found a few original articles on the 
combined subject of asthma and COVID-19. 
Because COVID19 is a new virus with the first 
outbreak since 3 months ago, we expected that 
there are a few articles on COVID-19 and 
asthma together. More than 50% of the data 
used in this review is expert comments at valid 
websites such as https://www.AAAAI.org or 
https://ginasthma.org. Although some of our 
data were of a weak quality, some high-quality 
data could be helping us in our work. 
Discussion 
Moore from American Academy of Allergy, 
Asthma & Immunology (AAAAI) believed that 
the controller medications of ICS should not be 
stopped. Useless of maintenance medication 
will put the patient at risk for developing an 
asthma exacerbation.15 ICSs are commonly 
considered as a safe treatment for controlling 
asthma and would reduce the risk of an 
asthma attack by viruses for example  
COVID-19. This comment has a weak medical 
evidence base.11 COVID-19 may be higher in 
asthma and induce an asthma attack, 
pneumonia, and acute respiratory disease. 
Because there is no specific treatment of 
COVID-19 currently, preventive ways are the 
best management methods for this virus.16 
Patients with asthma should continue their ICS 
during the COVID-19 epidemic even while 
prescribing oral corticosteroids. Because, 
stopping ICS is often leads to a potential risk of 
an asthma attack. Therefore, keep your 
treatment, and in more severe conditions, 
follow the instructions on your asthma action 
plan. These recommendations apply to both 
adults and children with asthma.17 According 
to the CDC recommendations, patients with 
asthma are among those at a higher risk of 
COVID-19. Asthma experts recommend that 
patients must keep using their preventive 
inhalers during this pandemic because the first 
defensive action against this infection is the 
proper control of asthma. Mitchell Grayson 
from Asthma and Allergy Foundation of 
America (AAFA) and Michael Blaiss from 
American College of Allergy, Asthma and 
Immunology (ACAAI) believed that patients 
with asthma need to continue their preventive 
steroids.18 In an experience in China, it was 
identified that prolonged and high-dose 
corticosteroid is a great risk factor for  
COVID-19 death, therefore,  the corticosteroid 
should not be used for the management of 
COVID-19-induced lung injury or shock 
(Russell et al.).18 Patients with asthma who stay 
on their preventive medication do not have 
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hospitalizations with COVID-19.18 Generally, 
corticosteroid is not recommended for the 
treatment of COVID-19 pneumonia.19 But, 
corticosteroids associated with ventilator 
support should be considered for patients with 
severe conditions to prevent development of 
acute respiratory distress syndrome (ARDS).20 
In a study, 25 (69.44%) of 36 patients were 
treated with glucocorticoids.21 Systemic 
steroids such as cortisone, prednisolone, and 
dexamethasone along with fluticasone (ICS) 
did not suppress viral growth. Ciclesonide and 
mometasone also suppressed replication of 
other coronaviruses, HCoV-229E, and  
SARS-CoV, but not the replication of 
respiratory syncytial virus (RSV) or influenza 
virus. Ciclesonide is a safe drug that can be 
administered to infants at high 
concentrations.22 There is little data that 
asthma is more common among patients with 
COVID-19 or vice versa, the COVID-19 is more 
common in patients with asthma. In a study, 
9/140 of patients with COVID-19 were also 
with asthma complication.23 In a study in 
South Korea, asthma was not common in 
patients with COVID-19.24 The prevalence of 
asthma is not common among patients with 
COVID-19, with the estimated prevalence of 
only 4.2%.25  
Patients with asthma and COVID-19 
infection would continue to treat asthma 
according to present asthma guidelines,14 
which the inhaler method is better for the 
treatment of asthma. Nebulizer is not 
suggested because of its contamination and 
spreading viruses, therefore, metered-dose 
inhaler (MDI) is better.26 Biological agents such 
as anti-Interleukin (IL)-5, anti-IL-4/IL-13, and 
anti-IgE are recommended in the treatment of 
asthma.27,28 Partially controlled or uncontrolled 
asthma is a particular risk for COVID-19 
because the virus has more tendency to 
involve the respiratory tract.29 Table 1 shows a 
triage approach to asthma management during 
the COVID-19 pandemic.  
Table 1. Triage approach to patients with an 
asthma exacerbation during a pandemic 
Patient condition Action 
High COVID risk  
Low asthma severity risk  
Appropriately tested per 
CDC and state protocols 
with telehealth 
management of asthma  
High COVID risk  
High asthma severity 
risk or uncertain 
diagnosis  
Need for face to face 
evaluation with potential 
availability of PPE and 
negative pressure isolation 
if an aerosol generating 
procedure is anticipated  
Low COVID risk  
Low asthma severity risk 
Telehealth management  
Low COVID risk  
High  asthma severity 
risk or uncertain 
diagnosis  
Need for face to face 
evaluation which may 
occur in primary care or 
allergy clinic  
PPE: Personal protective equipment; CDC: Centers for Disease 
Control and Prevention; COVID: Coronavirus 
 
Corticosteroids are the typical treatment 
recommended in asthma or chronic obstructive 
pulmonary disease (COPD) exacerbation. The 
routine use of corticosteroids in patients with 
COVID-19 without obstructive lung disease is 
not advised as it may prolong viral 
replication.30,31 Moewover, Eric Macy believed 
that the treatment of asthma exacerbations in 
people with COVID-19 is the same as with any 
other virally induced asthma attack.32 The role 
of corticosteroids is unclear; while current 
international consensus and World health 
Organization (WHO) do not recommend  
them, Chinese guidelines do recommend short 
term therapy with low-to-moderate dose 
corticosteroids in COVID-19 ARDS.33-35 
There are not enough high quality articles 
on COVID-19 and asthma reciprocal effect. 
This was the main limitation of this study.  
Conclusion 
Patients with asthma need to continue on their 
preventive asthma medication, such as inhaled 
corticosteroids in pandemic COVID-19. The 
claim that patients with asthma are at higher 
risk of contracting COVID-19 is not clear. 
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drug and can be administered to infants at 
high concentrations. MDIs were suggested,  
but not nebulizer.  
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